ProBioGen, Tizona Ink License and Manufacturing Pact

ProBioGen  and Tizona Therapeutics have signed a commercial license and service agreement for cell line and process development. ProBioGen will develop Tizona’s immuno-oncology antibody up to GMP manufacturing, using its GlymaxX cell line to boost the antibody’s ADCC anti-tumor activity.
 
The program will follow ProBioGen’s development path, which, according to the company, allows selecting superior, stable producer clones with robust process features in reduced time, facilitating the earlier onset of clinical trials. ProBioGen will manufacture clinical materials at its new facility, which will house two additional 1,000L single-use bioreactors in its GMP suites.
 
Volker Sandig, ProBioGen’s chief scientific officer said, “We were impressed by the scientific approach and quality of work which Tizona has invested into this product candidate already, and we are looking forward to combining our expertise with that of Tizona for this very promising product candidate.”
 
Tizona’s chief operating officer, Jeremy Bender, said, “We were seeking a high quality service provider with a proven track record and a robust ADCC enhancement technology for our project, and ProBioGen’s package of technical and scientific expertise, timelines, financial terms and, importantly, people behind it, were a compelling combination.”